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Abstract: Iodothyronine deiodinases (Dios) are involved in the regioselective removal of iodine from
thyroid hormones (THs). Deiodination is essential to maintain TH homeostasis, and disruption
can have detrimental effects. Halogen bonding (XB) to the selenium of the selenocysteine (Sec)
residue in the Dio active site has been proposed to contribute to the mechanism for iodine removal.
Polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) are known disruptors
of various pathways of the endocrine system. Experimental evidence shows PBDEs and their
hydroxylated metabolites (OH-BDEs) can inhibit Dio, while data regarding PCB inhibition are limited.
These xenobiotics could inhibit Dio activity by competitively binding to the active site Sec through
XB to prevent deiodination. XB interactions calculated using density functional theory (DFT) of THs,
PBDEs, and PCBs to a methyl selenolate (MeSe−) arrange XB strengths in the order THs > PBDEs >
PCBs in agreement with known XB trends. THs have the lowest energy C–X*-type unoccupied orbitals
and overlap with the Se lp donor leads to high donor-acceptor energies and the greatest activation of
the C–X bond. The higher energy C–Br* and C–Cl* orbitals similarly result in weaker donor-acceptor
complexes and less activation of the C–X bond. Comparison of the I···Se interactions for the TH group
suggest that a threshold XB strength may be required for dehalogenation. Only highly brominated
PBDEs have binding energies in the same range as THs, suggesting that these compounds may inhibit
Dio and undergo debromination. While these small models provide insight on the I···Se XB interaction
itself, interactions with other active site residues are governed by regioselective preferences observed
in Dios.
Keywords: iodothyronine deiodinase; halogen bonding; xenobiotics; endocrine disruption;
polybrominated diphenyl ethers (PBDEs); polychlorinated biphenyls (PCBs); thyroid hormones (THs)
1. Introduction
Thyroid hormones (THs) are essential biomolecules involved in many biochemical processes,
particularly in early developmental stages [1–5]. The prohormone thyroxine (3,3′,5,5′-tetraiodothyronine,
T4), and to a lesser extent, 3,3′,5-triiodothyronine (T3) are secreted from the thyroid gland upon
stimulation by thyroid stimulating hormone (TSH) [6]. Transport proteins (TPs), such as thyroglobulin
(TBG) and transthyretin (TTR), transport THs to target cells based on metabolic and/or developmental
needs [1].
Upon reaching target cells, deiodination by the iodothyronine deiodinase (Dio) family of
selenoproteins modulates TH signaling by controlling levels of the active metabolite T3 (Figure 1) [1].
Deiodination of the outer (phenolic) ring or inner (tyrosyl) ring of THs are activating and inactivating
pathways respectively. For example, outer-ring deiodination (ORD) of T4 by Type I (Dio1) or Type II
(Dio2) deiodinases produces active T3, while inner-ring deiodination (IRD) of T4 by Type III (Dio3,
and Dio1 to a lesser extent) produces the inactive metabolite 3,3′,5′-triiodothyronine or reverse T3
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(rT3) (Figure 1). Dio3 also lowers T3 concentrations through conversion to 3,3′-diiodothyronine (T2).
Deiodination is facilitated by a rare selenocysteine (Sec) residue within the cleft of the active site [7].
Disruption of TH homeostasis by xenobiotics can have long-term negative health effects such as
structural abnormalities, cardiovascular diseases, and hypo/hyperthyroidism [1,8]. Organohalogen
compounds, such as polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls
(PCBs), are known endocrine-disrupting compounds that induce a range of developmental and
neurodegenerative effects [9–20]. Recently, studies have shown that inhibition of Dio activity may
be one pathway for disruption [21–24]. Related halogenated compounds such as polybrominated
biphenyls (PBBs) and polychlorinated diphenyl ethers (PCDEs) have been shown to alter TH levels
but have not yet been shown to inhibit Dio [25–27].
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Industrial runoff of these compounds into the environment has led to bioaccumulation in organisms 
over time, leading to contamination in wildlife [32–36]. Enzymatic debromination of higher-order 
PBDEs (> 5 Br) contributes to more efficient bioaccumulation [30,37]. Hydroxylated metabolites (OH-
BDEs) have been shown to inhibit TRβ in silico and in vitro [38,39]. There is evidence for Dio 




Figure 1. Mechanistic pathways of deiodination by each deiodinase with thyroid hormone (TH)
substrates. Dio is regioselective for outer-ring or inner-ring deiodination (ORD and IRD, respectively).
PBDEs are used in commercial products to increase flame resistance (Figure 2a) [28,29]. However,
PBDEs contaminate house dust, leading to exposure via ingestion or inhalation [21]. As a result, some
formulations, namely the penta- and octa-BDEs, were banned in the early 2000s [30,31]. Industrial
runoff of these compounds into the environment has led to bioaccumulation in organisms over time,
leading to contamination in wildlife [32–36]. Enzymatic debromination of higher-order PBDEs (>5 Br)
contributes to more efficient bioaccumulation [30,37]. Hydroxylated metabolites (OH-BDEs) have been
shown to inhibit TRβ in silico and in vitro [38,39]. There is evidence for Dio inhibition by PBDEs and
OH-BDEs in fish, birds, and humans [21,37,40,41].
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Figure 2. Examples of (a) polybrominated diphenyl ethers (PBDEs)—BDE-47 and 3-HO-BDE-47;
(b) polychlorinated biphenyls (PCBs)—PCB-77 and triclosan.
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PCBs, like PBDEs, are industrial flame retardants with high chemical stability (Figure 2b) [42,43].
Production of some PCB formulations were banned in the 1970s, but they still contaminate urban
areas [44–47]. These organohalogens are classified into two subcategories—coplanar or dioxin-like
(having no ortho chlorines) and non-coplanar or non-dioxin-like (having one or more ortho chlorines).
Dioxin-like PCBs are highly toxic, which is often attributed to an assumed structural similarity with
tetrachlorodibenzodioxin (TCDD), a known inhibitor of the aryl hydrocarbon receptor (AhR) [48].
Non-dioxin-like PCBs are toxic at higher concentrations and inhibit TBG and TTR [49–52]. PCBs
have been reported to disrupt TH homeostasis through other mechanisms, such as the sodium-iodide
symporter (NIS) [51,53–56]. Limited experimental data suggest that PCBs disrupt TH levels, which
could indicate Dio inhibition [57–59]. The hydroxylated compound triclosan has been shown to weakly
inhibit Dio (Figure 2b) [60].
Halogen bonding (XB) has gained importance in drug design and crystal engineering [61–70].
Our group has proposed that XB participates in the Dio mechanism through the formation of an initial
Se···I interaction between the selenium of the active site Sec residue and a TH iodine (Figure 3) [71].
This mechanism is supported by the work of Mugesh et al. on naphthyl-based deiodinase mimics
which display high activity through a combination of halogen and chalcogen bonding [72]. In addition,
Schweizer et al. identified potential proton channels in their X-ray structure of the Dio3 catalytic
domain that support the XB-based mechanism [7]. Dios prefer the rare Sec residue due to its high
nucleophilicity relative to Cys, which is enhanced by deprotonation at physiological conditions. Recent
studies by our group explored the possibility that organohalogens like PCBs and PBDEs could inhibit
Dio activity by blocking the active site through an X···Se halogen bonding (XB) interaction [28,73].
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[42,66,74–82]. Briefly stated, one side describes XB as driven primarily by electrostatics, where the 
donor interacts with an area of positive electrostatic potential on the distal end of the R‒X bond, 
commonly called the “σ-hole” [68,83,84]. This “polar flattening” results from electron density 
depletion along the R‒X bond axis, leading to the halogen to adopt an anisotropic, oblate shape 
[67,85–87]. Groups on the other side note charge transfer as a significant contributor to XB and use 
descriptions in terms of valence bond theory or molecular orbital (MO) interactions related to early 
contributions by Mulliken [71,80,88–94]. Our group’s discussion of XB in Dio activity has focused on 
this latter MO description to define XB as a donor-acceptor interaction between the lone pair of a 
nucleophile (σlp) and the antibonding orbital (σR-X*) on the acceptor fragment (Figure 4). According 
to this model, XB is strengthened for (a) Lewis acids with weaker R‒X bonds, which have lower lying 
σR-X* MOs, and (b) stronger Lewis bases due to destabilization of the lp donor MOs. In Dio, a partial 
explanation for the preference of Sec of Cys is the greater Lewis basicity of the selenolate over the 
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reference [71]. The identities of B and their protonation states have not been deter ined.
An ongoing debate on the driving forces for the XB interaction has raged in the literature [42,66,74–82].
Briefly stated, one side describes XB as driven primarily by electrostatics, where the donor interacts
with an area of positive electrostatic potential on the distal end of the R–X bond, commonly called the
“σ-hole” [68,83,84]. This “polar flattening” results from electron density depletion along the R–X bond
axis, leading to the halogen to adopt an anisotropic, oblate shape [67,85–87]. Groups on the other side
note charge transfer as a significant contributor to XB and use descriptions in terms of valence bond
theory or molecular orbital (MO) interactions related to early contributions by Mulliken [71,80,88–94].
Our group’s discussion of XB in Dio activity has focused on this latter MO description to define XB as
a donor-acceptor interaction between the lone pair of a nucleophile (σlp) and the antibonding orbital
(σR-X*) on the acceptor fragment (Figure 4). According to this model, XB is strengthened for (a) Lewis
acids with weaker R–X bonds, which have lower lying σR-X* MOs, and (b) stronger Lewis bases due
to destabilization of the lp donor MOs. In Dio, a partial explanation for the preference of Sec of Cys
is the greater Lewis basicity of the selenolate over the thiolate [71]. In peri-chalcogen-substituted
naphthyl-based Dio mimics, strong nucleophiles have higher Dio-like activity (i.e., Se,Se > Se,S > S,S),
consistent with the preference for selenium over sulfur [95,96]. Natural Bond Orbital (NBO) theory can
be used to calculate the donor-acceptor energy (∆ED→A) as the extent to which donation into the σR-X*
acceptor stabilizes of the lp donor MO (Figure 4) [71,97]. The trend in ∆ED→A for organohalogens is
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consistent with increasing XB strength with halogen size. The increased donation into σR-X* leads to
more activated C–X bonds (i.e., C–I > C–Br > C–Cl for both ∆d(C–X) and ∆ED→A) (Figure 4) [28].
Overlap with the donor MO is enhanced when the acceptor σR-X* MO has a greater contribution
from the halide AOs. Decreasing the electronegativity from F to I causes the X AOs to destabilize
relative to the R fragment, resulting in orbitals with more ‘R’-like character in σR-X while increasing
the X contribution (%X) to σR-X* [66]. The shift in the R character of σR-X depletes the electron density
along the bond axis only, consistent with the observation of a σ-hole in the electrostatic potential [84].
XB interactions have also been described using a more complex MO diagram for the mixing of both
σR-X and σR-X* with the donor MO, resulting in an interaction similar to the 3c4e hypervalent bond
observed in the trihalide I3− (Figure 4) [89,90,98–100]. Maximization of the overlap between σlp and
σR-X* requires a near 180◦ R–X···Y angle, where Y is the donor. Many protein-ligand XB interactions
fall in the range of 140◦ to 160◦ [65,101–103].
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Figure 4. XB as described by the molecular orbital (MO) model showing the interaction between a lone
pair of a donor and the R–X antibonding orbital, alongside the corresponding average stabilization
of the Se donor lone pair by THs, PBDEs, and PCBs as determined by Natural Bond Orbital (NBO)
∆ED→A analysis. Units are kcal mol−1. Adapted from reference [66].
2. Summary of XB Models Related to Dio Activity
2.1. Thyroid Hormone (TH) I···Se XB Interactions
XB is observed in X-ray structures of TH binding proteins, such as TTR and TBG, primarily
in the form of weak I···O bonds (i.e., PDB entries 1SNO, 2CEO) [71,104–106]. I···Se XB interactions
are found in the T4 lysozyme (selenomethionine mutant, PDB 3DN3) as well as aromatic crystalline
systems [91,107]. In Dio, the nucleophilic selenium is assumed to form a strong I···Se XB interaction
which activates the C–I bond (Figure 3). Trends in density functional theory (DFT) interaction energies
for the series of THs (T4, T3, rT3, 3,3′-T2, 3,5-T2, 3′,5′-T2, 3-T1, 3′-T1) were calculated using MeSe− as a
minimalistic model of Dio’s active site Sec at each unique position on the outer and inner rings [28].
The stronger nucleophilicity of MeSe− results in larger donor-acceptor energy interactions compared
to sulfur analogues [71,72]. Manna et al. found the same trends in XB interactions of T4,T3, rT3, and
3,3′-T2 using methylselenol (MeSeH), but with interactions approximately an order of magnitude
weaker due to the neutral donor [72]. In either case, trends in XB strength do not correlate with Dio
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regioselectivity, which is governed by other factors, such as interactions with residues within the active
site that are omitted from the simple DFT models. For example, weaker I···O and I···N XB interactions
between ancillary iodines and adjacent residues may help stabilize the TH substrate within the active
site [104,108]. These additional XB interactions may enhance the preference towards the outer or
inner ring and stabilize the substrate within the active site. The conformation of the TH may also
be important, as substrates may need to fit in the active site in a certain way to allow for binding.
Crystallographic data from the Protein Data Bank suggest proteins bind THs in cisoid (both phenyl
rings on same side as ether linkage) or transoid (both phenyl rings on opposite sides of ether linkage)
conformations [104].
Based upon the MO model (Figure 4), XB trends are understood in terms of the orbital energy
and C–I* character of the lowest unoccupied molecular orbitals (LUMOs) [28]. In addition, XB
favorability and activation of the C–X bond can be calculated in terms of corrected zero-point
interaction energies (∆EZPE) for formation of the XB complex and NBO donor-acceptor energies
(∆ED→A), respectively [28,71]. XB is generally more favorable for diiodinated rings compared to
monoiodinated rings (Table 1). Increased donation into the σR-I* MO leads to stronger I···Se interactions
and a larger activation of the C–I bond in agreement with the MO model. Interaction strengths
positively correlate with C–I* LUMO energies within each TH subgroup (inner-mono < outer-mono
≤ outer-di < inner-di) (Figure 5) [28]. These results suggest that specific substitution patterns, such
as outer-diiodinated THs, may be more suitable for targeting Dio2, while inner-diiodinated THs
prefer Dio3. This prediction is consistent with the preferred substrates of Dio2 (rT3) and Dio3 T3
(3,5-diiodothyronine) [109]. For example, based upon DFT XB strengths, the deiodination reaction
of T4 would first occur at the outer-ring (T3) with subsequent deiodination on the opposite ring to
3,3′-T2 (Table 1 and Figure 2) [28]. These results are consistent with the preferred substrate and
regioselectivity of Dio3, which favors T3 (IRD). However, these results do not represent a general
trend in Dio regioselectivity given that Dio2 acts upon the outer ring iodine of T4, which has a weaker
interaction than the inner ring. Additionally, 3-T1 is not deiodinated to thyronine (T0) and has the
least favorable XB interaction to SeMe−, suggesting that a threshold interaction strength must be met
to cleave the C–I bond (Figure 3). For example, T4 has a high ∆EZPE (−29.59 kcal mol−1) and a more
lengthened C–I bond (∆d(C–I) = +0.198 Å) compared to 3-T1 (∆EZPE = −21.41, ∆d(C–I) = +0.158 Å)
(Table 1). A minimum donation into σR-X*, which is related to the overall strength of the R–X bond,
may be required to convert the XB interaction to a nucleophilic attack. The inability of 3-T1 to undergo
dehalogenation by Dio suggest that it may only reversibly bind to the active site of Dio [110].
Table 1. Interaction energies and selected distances for halogen bonding (XB) complexes of TH
analogues with MeSe− at each unique iodine center, adapted from reference [28].
Compound XB Position d(C–I), Å;





T4 Inner 2.300 (+0.198) 2.917 −29.59 53.58, 4.18 [a]
T4 Outer 2.282 (+0.169) 2.960 −29.50 45.93, 3.83 [a]
T3 Inner 2.299 (+0.197) 2.922 −28.43 52.87, 3.96 [a]
T3 Outer 2.256 (+0.144) 3.006 −24.84 40.25, 3.03 [a]
rT3 Inner 2.276 (+0.174) 2.953 −25.14 48.43, 3.17 [a]
rT3 Outer 2.291 (+0.190) 2.946 −33.07 48.98, 4.12 [a]
3,3′-T2 Inner 2.272 (+0.169) 2.960 −23.56 46.89, 3.20 [a]
3,3′-T2 Outer 2.265 (+0.153) 2.990 −28.46 43.06, 3.61 [a]
3,5-T2 Inner 2.286 (+0.184) 2.942 −26.61 48.51
3′,5′-T2 Outer 2.286 (+0.173) 2.954 −32.02 47.48
3-T1 Inner 2.262 (+0.158) 2.980 −21.41 43.43
3′-T1 Outer 2.260 (+0.158) 3.002 −27.29 41.18
[a] Donor-acceptor energies with MeSeH from reference [96].
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2.2. Polybrominated Diphenyl Ether (PBDE) Br···Se XB Interactions
Br···Se XB teractions were modeled for a sel ction of PBDEs and hydroxylated PBDEs (OH-BDEs)
with MeSe− at each unique halogen position (ortho, meta, or para) (Figure 6) [21]. In general, XB
interactions of PBDEs are less favorable compared to THs, consistent with the XB trends favoring
larger halogens (I > Br > Cl). In PBDEs, XB interactions are favored at the ortho and meta positions
which have more activated C–Br bonds. Increased halogenation of PBDEs generally leads to increased
activation of C–Br bonds due to lowering of the σR-X* acceptor MOs for stronger interactions. XB
favorability in PBDEs/OH-BDEs is consistent with the observed ortho and meta iodination positions of
THs. The stronger XB interactions at the ortho and meta positions of halogenated diphenyl ethers may
be related to the adaptation of THs to biological systems in conjunction with the higher nucleophilicity
of Sec. PBDEs with ortho and meta substitutions, such as BDE-73, may be better inhibitors of Dio [28].
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Some of the highly brominated PBDEs/OH-BDE (≥5 Br) complexes have donor-acceptor interaction
energies in the same range as THs. For example, in 6-HO-BDE-47, the strong interaction at the 2′
position (∆ED→A = 44.77 kcal mol−1, ∆d(C–Br) = +0.206 Å) is in the same range of THs and could
be susceptible to debromination (Figure 6). However, interaction at the 4′ position is much weaker
(∆ED→A = 21.12 kcal mol−1, ∆d(C–Br) = +0.102 Å) and may be less likely to undergo debromination
(Figure 6). In DFT studies, XB favorability was enhanced by the proximity of -OH to the XB interaction
site [28]. For example, in BDE-47, XB is more favorable at the ortho (∆EZPE = −17.54 kcal mol−1)
compared to para (∆EZPE = −16.62 kcal mol−1). However, upon hydroxylation, XB at the para position
of 5-HO-BDE-47 (∆EZPE = −21.65 kcal mol−1) is enhanced by the proximal OH group for a more
favorable interaction than ortho (∆EZPE = −16.53 kcal mol−1) (Figure 7). In OH-BDEs, the -OH group
may aid in substrate recognition to Dio by better mimicking TH binding. Schweizer et al. proposed
that T4 was held in the Dio3 active site by a His202-Arg275 clamp through which His202 forms a
hydrogen bond to the T4 4′-OH group (Figure 8) [7].
Molecules 2020, 25, x FOR PEER REVIEW 7 of 16 
 
Figure 6. Sample structures of PBDEs and the hydroxylated metabolites of BDE-47. 
Some of the highly brominated PBDEs/OH-BDE (≥ 5 Br) complexes have donor-acceptor 
interaction energies in the same range as THs. For example, in 6-HO-BDE-47, the strong interaction 
at the 2′ position (ΔED→A = 44.77 kcal mol−1, Δd(C‒Br) = +0.206 Å) is in the same range of THs and could 
be susceptible to debromination (Figure 6). However, interaction at the 4′ position is much weaker 
(ΔED→A = 21.12 kcal mol−1, Δd(C‒Br) = +0.102 Å) and may be less likely to undergo debromination 
(Figure 6). In DFT studies, XB favorability was enhanced by the proximity of -OH to the XB 
interaction site [28]. For example, in BDE-47, XB is more favorable at the ortho (ΔEZPE = −17.54 kcal 
mol−1) compared to para (ΔEZPE = −16.62 kcal mol−1). However, upon hydroxylation, XB at the para 
position of 5-HO-BDE-47 (ΔEZPE = −21.65 kcal mol−1) is enhanced by the proximal OH group for a 
more favorable interaction than ortho (ΔEZPE = −16.53 kcal mol−1) (Figure 7). In OH-BDEs, the -OH 
group may aid in substrate recognition to Dio by better mimicking TH binding. Schweizer et al. 
proposed that T4 was held in the Dio3 active site by a His202-Arg275 clamp through which His202 




Figure 7. Density functional theory (DFT) optimized structures of XB complexes at the ortho and para 
positions of hydroxylated BDE-47 metabolites. Distances are in Angstroms. 
 
Figure 8. Structures of the active site of the crystal structure of Dio3 (PDB = 4TR4) with Sec170 and 
the residues of the His202-Arg275 clamp proposed by Schweizer et al. indicated [7]. 
Various studies suggest the potential for PBDEs to inhibit Dio to varying degrees [21,60,111]. For 
example, François et al. found an increase in Dio1 activity at a 1.0 nM concentration of BDE-209, but 
Figure 7. Density functional theory (DFT) optimized structures of XB complexes at the ortho and para
positions of hydroxylated BDE-47 metabolites. Distances are in Angstroms.
Molecules 2020, 25, x FOR PEER REVIEW 7 of 16 
 
Figure 6. Sample structures of PBDEs and the hydroxylated metabolites of BDE-47. 
Some of the highly brominated PBDEs/OH-BDE (≥ 5 Br) complexes have donor-acceptor 
interaction energies in the same range as THs. For example, in 6-HO-BDE-47, the strong interaction 
at the 2′ position (ΔED→A = 44.77 kcal mol−1, Δd(C‒Br) = +0.206 Å) is i  the same range of THs and could 
be susceptible to debromination (Figure 6). However, interaction at the 4′ position is much weaker 
(ΔED→A = 21.12 kcal mol−1, Δd(C‒Br) = +0.102 Å) and may be less likely o undergo debromination 
(Figure 6). In DFT studies, XB favorability was enhanced by the proximity of -OH to the XB 
interaction site [28]. or example, in BDE-47, XB is more favorable at the o tho (ΔEZPE = −17.54 kcal 
mol−1) compared to para (ΔEZPE = −16.62 kcal mol−1). However, upon hydroxyla ion, XB at the para 
positi n of 5-HO-BDE-47 (ΔEZP  = −21.65 kcal mol−1) is enhanced by the proximal OH group for a 
more fav rable interaction than ortho (ΔEZPE = −16.53 kcal mol−1) (Figure 7). In OH-BDEs, the -OH 
group may aid in substrate recog ition to Dio by better mimicking TH binding. Schweizer et al. 
proposed that T4 was held in the Di 3 active site by a His202-Arg275 clamp through which His202 




Figure 7. Density functional theory (DFT) optimized structures of XB complexes at the ortho and para 
positions of hydroxylated BDE-47 metabolites. Distances are in Angstroms. 
 
Figure 8. Structures of the active site of the crystal structure of Dio3 (PDB = 4TR4) with Sec170 and 
the residu s of the His202-Arg275 clamp proposed by Schweizer et al. indicated [7]. 
Various studies suggest the potential for PBDEs to inhibit Dio to varying degrees [21,60,111]. For 
example, Françoi  et al. fo nd an increase in Dio1 activity at a 1.0 nM c ncentration of BDE-209, but 
Figure 8. Structures of the active site of the crystal structure of Dio3 (PDB = 4TR4) with Sec170 and the
residues of the His202-Arg275 clamp proposed by Schweizer et al. indicated [7].
Various studies suggest the potential for PBDEs to inhibit Dio to varying degrees [21,60,111]. For
example, François et al. found an increase in Dio1 activity at a 1.0 nM concentration of BDE-209, but
not at 0.5 nM or 2.0 nM [41]. In addition, 3-HO-BDE-47 inhibits Dio2, although 6-HO-BDE-47 showed
no activity [21]. The difference in XB favorability between 3-HO-BDE-47 and 6-HO-BDE-47 suggest
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hydrogen bonding of a hydroxyl group adjacent to the XB-interacting Br may aid substrate binding
in TH binding proteins. In comparing Dio2 inhibition activity of 3-HO-BDE-47 and 5′-HO-BDE-99,
the former had a more favorable XB interaction to our small active site model (at the para position
adjacent to the –OH group) [60,111]. Factors such as interactions at the active site not included in
our minimalistic model may govern the preference of Dio2 inhibition. In another study, a series of
pentabrominated PBDEs (BDE-28, 33, 47, and 100) (∆EZPE ≈ −13.00 to −23.00 kcal mol−1) showed a
positive correlation between concentration and free T3 levels, suggesting Dio1 inhibition. However,
other mechanisms may be disrupted, such as displacement of THs from transport proteins [112].
Animal studies have shown that PBDEs are debrominated by Dios [21,41,113]. Out of a series
of 20 PBDEs, Roberts et al. showed that six (BDEs 99, 153, 183, 203, 208, and 209) (∆EZPE ≈ −19.00 to
−29.00 kcal mol−1) undergo debromination in common carp, rainbow trout, and chinook salmon [21].
The interaction energies for these examples are close to or exceed that of 3-T1, providing support
for the potential for a threshold XB strength needed for dehalogenation. Across all three species,
meta-substituted PBDEs were the preferred substrates, however the preference for debromination
varied across species. In carp, debromination was preferred at the meta position, while trout and
salmon preferred debromination at the ortho position [21]. They found that neither BDE-49 nor
BDE-154 undergo dehalogenation in any of the species. Avian studies have shown that consumption
of BDE-209 lead to increased concentrations of octa- and nona-BDEs (BDEs 196, 197, 203, 207, and
208) [41,113]. The differences in observed debrominated products and regioselective preferences for
debromination suggest different Dios are targeted across species. For instance, in carp, preference for
deiodination at the meta position suggests a higher affinity for Dio2, while the ortho preference in
trout and salmon may suggest better inhibition of Dio3.
2.3. Polychlorinated Biphenyl (PCB) Cl···Se XB Interactions
Modeling of the Cl···Se XB interactions for all possible 209 PCB congeners at each unique XB
position found that PCBs have much weaker XB interactions than PBDEs and THs (Figure 9), as expected
based on the trend of XB strength in the order of I > Br > Cl [73]. XB interactions for PCBs are more
favorable at the ortho position, consistent with PBDE XB interactions. On average, meta and para XB
interactions that contain two flanking halogens cluster towards a higher ∆ED→A (Figures 10 and 11).
None of the PCBs, even the highly chlorinated compounds, have ∆EZPE values in the range of THs,
suggesting dechlorination by Dio is unlikely (Figure 8).Molecules 2020, 25, x FOR PEER REVIEW 9 of 16 
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The weaker XB interactions in PCBs is attributed to their stronger C–Cl bonds and the higher
energy σC-Cl* acceptor orbitals compared to the bromo- and iodoaromatics [66]. The C–Cl bonds are
so strong that the π* MOs are the LUMOs rather than the σC-Cl*-type orbitals. These orbitals are also
less weighted toward Cl, leading to less overlap with the Se lp. (%X contributions to σC-Cl* in PCBs
are 45–48% compared to aryl bromides (50–55%) and aryl iodides (55–65%) (Figure 9) [66]. Meta
and para XB interactions also generally have higher %X values compared to ortho XB interactions,
consistent with their stronger ∆ED→A values. The slightly more favorable XB interactions for meta and
para chlorides flanked by two halogens are attributed to the electron-withdrawing properties of the
neighboring substituents, which stabilizes the σC-Cl* acceptor MO [73].
Experimental evidence for Dio inhibition by PCBs is limited and shows conflicting results [57,58,114].
For example, Dio3 activity increased in the brain upon exposure to Aroclor 1254, a mixture containing
primarily PCB-77, but hepatic Dio1 and brain Dio2 activity decreased [114]. In contrast, neither PCB-77
nor Aroclor 1254 had an effect on brain Dio2 activity in adult mice [58]. A recent study involving cord
blood showed a positive correlation between the concentration of 2,4,5-substituted PCBs and the T3/rT3
ratio, indicating Dio3 inhibition [57]. This negative effect on Dio3 activity is consistent with trends for
highly chlorinated PCBs and a hypothesis of blocking TH binding through an XB interaction. Trends
in XB favorability are also similar to a study involving TTR inhibition, which compared substitution
patterns of PCBs [115].
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3. Discussion
Modeling the XB interactions of halogenated endocrine disruptors with the Dio active site model
SeMe− model provide insight into potential mechanisms of inhibition. Xenobiotics such as PBDEs
and PCBs may inhibit Dio by forming an X···Se XB interaction to the catalytic Sec in the active site.
XB favorability in the order of THs > PBDEs > PCBs agrees with the expected trends (I > Br > Cl).
THs generally undergo deiodination by Dios, an exception being 3-T1 which has the weakest I···Se
XB interaction of the series. This observation suggests that XB interaction strength with the active
site Sec must exceed an energy threshold for deiodination. While some of the highly substituted
PBDEs/OH-BDEs have similar interaction energies to THs and may undergo debromination, PCBs
have less favorable interactions, suggesting dechlorination by Dio would not be observed.
XB interaction strengths vary by position. The preference for XB at the meta and ortho positions
of diphenyl ethers suggests that the substitution pattern of THs may have been selected to facilitate
enzymatic deiodination. The position dependence of XB interactions of PBDEs (ortho and meta)
and PCBs (meta and para) suggest that these compounds may target Dio types with substitution
patterns similar to their preferred substrate [116]. For example, Dio1 performs both ORD (meta-)
and IRD (ortho-) (although there is a preference for ORD) with rT3 as its preferred substrate, while
Dio2 and Dio3 prefer ORD (meta-) and IRD (ortho-) with T4 and T3, respectively. A PCB, PBDE or
related compound with a structure containing solely meta halogens (such as PCB-80 or BDE-80), or its
strongest XB interactions at the meta position, may preferentially inhibit Dio2. Likewise, a PCB, PBDE
or related compound containing solely ortho chlorines (such as PCB-54 or BDE-54), or its strongest XB
interactions at the ortho position, may target Dio3 for inhibition. These preferences will be subject to
other interactions within the Dio active site. Understanding the regioselectivity of these preferences
may aid in the drug design to target specific Dios.
The conformational preferences of THs and halogenated aromatics will also affect Dio binding.
For instance, since PBDEs have the same diphenyl ether core as THs, they may bind to Dio in a similar
fashion. Xenobiotics with large halogens, such as THs and PBDEs, may be less able to adapt their
most favorable conformations to the active site due to steric interactions. PCBs lack the ether linkage
connecting the phenyl rings and are classified as dioxin or non-dioxin-like based on ortho-substitutions.
These two conformations differ in terms of toxicity—non-dioxin-like PCBs are only toxic at higher
concentrations (>1000 nM), while dioxin-like PCBs are highly toxic and mimic the structure of TCDD.
Addition of halogens to ortho positions restrain the PCB to a noncoplanar conformation due to
steric clashes, leading to lower flexibility around the central C-C bond [73]. Therefore, highly-ortho
chlorinated species have much lower conformational flexibility, which may impact the ability of the
PCB to adapt to the active site and inhibit the protein.
While these small models provide insight on the XB interactions in the active site of Dio, the simple
model itself is insufficient for describing various factors that may influence overall XB favorability.
Interactions with active site residues will control regioselective binding and activation of THs and
the ability of inhibitors to block the active site. For example, OH-substituted inhibitors may be
accommodated by the His-Arg clamp proposed for Dio3 [7]. The X···O and X···N XB interactions to
ancillary halogens may increase the stability of the TH substrate in the active site. Hydroxylated PCBs
and PBDEs that can interact with this clamp and form the X···Se interaction could be the most potent
inhibitors. Experimental studies of Dio with PCBs, PBDEs and related xenobiotics are necessary to
further explore the relationship between selectivity, inhibition, and substitution pattern.
From the modeling perspective, simulations of full proteins will be needed to understand how
these factors affect the XB interaction and substrate binding. Force fields have been developed to
account for XB interactions through the use of dummy atoms to represent the anisotropic density
at the halogen [117–121]. In addition, AutoDock VinaXB has been developed to include a halogen
bonding scoring function [122]. Calculating the free energies of binding (i.e., ∆G) may also be useful
for predicting favorability of protein-ligand interactions. MMPBSA and MMGBSA (and their variants)
and QM methods such as fragmented molecular orbital (FMO) could be used for such calculations and
Molecules 2020, 25, 1328 11 of 16
may aid in drug design for suitable inhibitors to target the active site of Dios [123–125]. Use of these
computational methods to understand the underlying mechanisms and key interactions in Dios with
an eye toward designing treatments for TH-related disorders is being pursued within our group.
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